Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine‐to‐Human Live Heart Transplant
Xenotransplantation · 2026-05 · 33 (3)
DOI: 10.1111/xen.70143 ↗Kurz gefasst
Fallbericht in der Zeitschrift Xenotransplantation, online erschienen am 27.05.2026. Verfasst von Michael A Cole und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Heart Transplantation, Transplantation, Heterologous, Complement Activation, Complement System Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, National Heart Lung Blood Institute Training Program in Hematology, Fondation pour la Recherche Médicale.
Abstract (Originalsprache)
Complement activation is a major barrier to xenotransplantation. We report detailed complement monitoring in a 58‐year‐old man who received a 10 gene–edited porcine heart expressing human complement regulators CD46 and CD55. Despite these transgenes and prophylactic systemic complement inhibition with C1 esterase inhibitor (C1INH), early surveillance biopsy on post‐operative day (POD) 13 showed significant histologic evidence of complement deposition with C3d and C4d within capillaries and endothelial activation. In light of these findings, treatment was escalated to terminal complement inhibition using eculizumab. Post‐operative complement activity was assessed via immunohistochemistry and dynamic ex vivo serum assays, including a novel bioluminescent modified Ham (bmHam) assay. Following eculizumab initiation, serum sC5b‐9 dropped to undetectable levels, and bmHam cytotoxicity decreased significantly, confirming terminal pathway inhibition. Dilutional bmHam assays further demonstrated stronger complement blockade with eculizumab than with C1INH. However, repeat transplant biopsy on POD 30 biopsy showed persistence of anti‐C4d+ and anti‐C3c+ staining, and increased C5b‐9 compared to POD13. This breakthrough was identified by the dilutional bmHam but was not detected by changes in CH50 or sC5b‐9. These findings highlight the potential need for early terminal complement inhibition and integrated functional monitoring as critical components of xenotransplant management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Cardiothoracic Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Clinical Nephrology Section, NIDDK, National Institutes of Health Clinical Research Center, Bethesda, Maryland, USA.
- Department of Medicine, University of Maryland School of Medicine, Program in Trauma, Baltimore, Maryland, USA.
- Centre de Recherche des Cordeliers, Institut National de La Santé Et De La Recherche Médicale, Sorbonne Université, Université De Paris Cité, Inflammation, Complement and Cancer Team, FHU COMET, Paris, France.
- Paris Institute for Transplantation and Organ Regeneration, INSERM U970, Université Paris Cité, Paris, France.
ORCID-Profile: Michael A Cole, Avneesh K Singh, Lo Tamburro, Robert A Brodsky, Muhammad M Mohiuddin, Alison Grazioli
Förderung
- National Institute of Allergy and Infectious Diseases
- National Heart Lung Blood Institute Training Program in Hematology
- Fondation pour la Recherche Médicale
- French-Speaking Society of Transplantation
- Philippe Foundation
- Institut Servier
- American Society of Hematology
- OrganX
Zitieren
APA
Cole, M. A., Tully, A., Galindo, J., Singh, A. K., Waldman, M., Athale, J., Boudhabhay, I., Morgand, E., Mezine, F., Goutaudier, V., Sannier, A., Lewis, B., Kain, J., Ero, M., Roumenina, L., Bruneval, P., Christenson, R., Tamburro, L., Burke, A., …, & Grazioli, A. (2026). Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine‐to‐Human Live Heart Transplant. Xenotransplantation, 33(3). https://doi.org/10.1111/xen.70143
Vancouver
Cole MA, Tully A, Galindo J, Singh AK, Waldman M, Athale J, et al. Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine‐to‐Human Live Heart Transplant. Xenotransplantation. 2026;33(3). doi:10.1111/xen.70143
BibTeX
@article{Cole2026,
author = {Cole, Michael A and Tully, Andy and Galindo, Javier and Singh, Avneesh K and Waldman, Meryl and Athale, Janhavi and Boudhabhay, Idris and Morgand, Erwan and Mezine, Fariza and Goutaudier, Valentin and Sannier, Aurélie and Lewis, Brad and Kain, Jamey and Ero, Mike and Roumenina, Lubka and Bruneval, Patrick and Christenson, Robert and Tamburro, Lo and Burke, Alan and Drachenburg, Cinthia and Loupy, Alexandre and Ayares, David and Brodsky, Robert A and Griffith, Bartley P and Mohiuddin, Muhammad M and Grazioli, Alison},
title = {Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine‐to‐Human Live Heart Transplant},
journal = {Xenotransplantation},
year = {2026},
volume = {33},
number = {3},
doi = {10.1111/xen.70143}
}
EUVIMED